DelveInsight recently conducted an in-depth MASH Market Size and Share Assessment to help a pharmaceutical client understand the evolving Metabolic Dysfunction-Associated Steatohepatitis (MASH) market ...
The Government of Canada is committed to safeguarding the health and well-being of Canada's agricultural community while supporting the long-term sustainability and success of the sector. Today, ahead ...
DelveInsight's "VERZENIO Market Size, Forecast, and Market Insight Report" highlights the details around VERZENIO, which is a ...
We recently compiled a list of the 10 Best Low Risk Stocks To Buy in 2025. In this article, we are going to take a look at ...
Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli ...
2d
Zacks Investment Research on MSNEli Lilly Rises 7.5% YTD: Time to Buy, Sell or Hold the Stock?Eli Lilly and Company’s LLY shares dipped almost 5% on Monday after rival Novo Nordisk NVO announced disappointing data from ...
Dr. Sarah M. Tolaney discusses breast practices associated with CDK4/6 inhibitors for the treatment of breast cancer.
Leerink 2025 Global Healthcare Conference March 10, 2025 9:20 AM ETCompany ParticipantsLucas Montarce - CFOMike Czapar ...
The Targeted Pulse: New Trial Evaluating Iadademstat/Azacitidine in MDS and Positive Trends in HNSCC
Forward steps are being made in HNSCC, and the first patient with MDS has been treated with iadademstat/azacitidine.
Verzenio plus Faslodex improved progression-free survival in HR+/HER2– advanced breast cancer after CDK/6i failure, with a ...
As VERZENIO gains traction in early-stage treatments and broadens its approved uses, its revenue is expected to keep growing. While the global CDK4/6 inhibitor market remains highly competitive ...
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results